Mediford offers a variety of contract services from establishment and banking of PDX-derived cell lines to conducting pharmacological studies at the GLP-certified facilities of Kumamoto Laboratories. The PDX models are more predictive of clinical outcomes than conventional "cancer cell lines" and will be useful for your research and development purposes.

Mediford provides various contract services using clinical isolates (PDC: Patient-Derived Cell) established at the National Cancer Center.

We provide a wide range of services in the development of regenerative medical products from consulting to medical writing for diseases that are difficult to treat with conventional methods. We support each stage of the development process up to submission of application for approval by providing contract services that meet a wide variety of research needs, including toxicity studies (GLP), efficacy and biodistribution studies (reliability standards), and medical writing at research facilities fully accredited by AAALAC.

Mass Spectrometry Imaging (MSI) is one of molecular imaging techniques. Its procedure consists of ionization of target molecules on a tissue section, determination with a mass spectrometer, and visualization of the distribution.

Mediford has been contracting PBMC separations in clinical trials for a long time. We pick up blood samples from study sites, and well-trained staffs operate PBMC isolation process at the GLP laboratory located at Itabashi, Tokyo.

Recently next generation pharmaceuticals are actively developed all over the world. Among them, oligonucleotide therapeutics (OGNs) are typical novel modalities which keep launching every year since 2016, and likely in development in the future.

Mediford offers reliable data to every modality with our technologies brushed up for a long time with low molecular drugs and cutting-edge instruments.